Tnfrsf10b Knockout cell line(MC38)
Catalog Number: KO01176
Price: Online Inquiry
Catalog Number: KO01176
Price: Online Inquiry
Product Information | |
---|---|
Product Name | Tnfrsf10b Knockout cell line(MC38) |
specification | 1*10^6 |
Storage and transportation | Dry ice preservation/T25 live cell transportation. |
Cell morphology | Epitheloid, semi-adherent semi-suspension cells |
Passage ratio | 1:2-1:4 |
species | Mouse |
Gene | Tnfrsf10b |
Gene ID | 21933 |
Build method | Electric rotation method / virus method |
Mycoplasma testing | Negative |
Cultivation system | 90% DMEM+10%FBS |
Parental Cell Line | MC38 |
Quality Control | Genotype: Tnfrsf10b Knockout cell line(MC38) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. |
Gene Information | |
---|---|
Gene Official Full Name | tumor necrosis factor receptor superfamily, member 10bprovided by MGI |
Also known as | MK; DR5; Ly98; KILLER; TRICKB; TRAILR2; TRICK2A; TRICK2B |
Gene Description | Predicted to enable TRAIL receptor activity; identical protein binding activity; and protease binding activity. Predicted to be involved in TRAIL-activated apoptotic signaling pathway; intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; and positive regulation of apoptotic process. Predicted to act upstream of or within apoptotic process and regulation of apoptotic process. Predicted to be located in Golgi apparatus; cytosol; and membrane raft. Predicted to be active in cell surface and plasma membrane. Is expressed in bladder; liver; renal vasculature; urethra of female; and urethra of male. Human ortholog(s) of this gene implicated in carcinoma (multiple); cervical cancer; hematologic cancer (multiple); and urinary bladder cancer. Orthologous to several human genes including TNFRSF10A (TNF receptor superfamily member 10a) and TNFRSF10B (TNF receptor superfamily member 10b). [provided by Alliance of Genome Resources, Apr 2025] |
Expression | Ubiquitous expression in limb E14.5 (RPKM 3.6), subcutaneous fat pad adult (RPKM 3.3) and 25 other tissues See more |
We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.
Cas9 Protein
Cas9 mRNA sgRNA
Cas9 Plasmid
Cas9 Virus
A – Exon KO
gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.
B - Frameshift KO
gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.
C - Complete KO
The entire gene coding sequence is deleted, achieving large-scale knockout effects.
KO Strategy Design
CRISPR Plasmid/Lentiviral Vector Construction
Lentiviral Packaging
Cell Transfection/Lentiviral Infection
Drug Selection
Cell Cryopreservation
Quality Control
Sequencing Validation
Monoclonal Cell Line Generation
Pool Efficiency Validation
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.